[Prognostic significance of the Mandard TRG classification after induction therapy in carcinoma of the oesophagus and cardia].
Mandard's tumor regression grade (TRG) is widely used to evaluate the pathological response to induction therapy with concurrent chemoradiotherapy in cancer of the oesophagus or gastro-oesophageal junction. The aim of this study was to evaluate the prognostic significance and clinical applicability of TRG. From 2000 to 2007, 108 patients with squamous cell carcinoma of the oesophagus (57 cases) or Siewert type I and II adenocarcinoma of the cardia (51 cases) were treated with induction chemoradiotherapy followed by surgery in the 1st Division of General Surgery of the University of Verona. The treatment was identical for all patients and consisted of cisplatin, 5 FU and docetaxel together with 50 Gy of concurrent radiotherapy. The treatment-induced response was evaluated by TRG. Fifty-one, 24, 17, 9 and 7 patients were classified, respectively, as TRG1, 2, 3 4 and 5. Fifty-two patients died of the disease. Disease-related survival decreased with the increase in TRG class in node-negative patients (p < 0.001), while in N+ patients it was poor, irrespective of TRG class (p = 0.241). Mandard TRG is therefore useful for staging patients undergoing preoperative chemoradiotherapy, because it displays high prognostic significance. In our study, however, N was the main prognostic factor and for this reason it is mandatory to consider nodal status along with TRG. Moreover, among N negative patients, the prognosis of each different TRG class is statistically different and for this reason different TRG classes cannot be grouped together.
I Divisione Clinicizzata di Chirurgia, Cattedra di Statistica Medica, Università di Verona.
Andrea
A
Zanoni
Giuseppe
G
Verlatoa
Annamaria
A
Minicozzi
Anna
A
Tomezzoli
Simone
S
Giacopuzzi
Mapriantonietta
M
Di Cosmo
Ilaria
I
Franceschetti
Edoardo
E
Saladino
Giovanni
G
De Manzoni
D000230:Adenocarcinoma / Q000145:classification* / Q000401:mortality / Q000628:therapy*; D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000145:classification* / Q000401:mortality / Q000628:therapy*; D002299:Cardia; D004938:Esophageal Neoplasms / Q000145:classification* / Q000401:mortality / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D013274:Stomach Neoplasms / Q000145:classification* / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate